Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03814746 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03814746 · ClinicalTrials.gov record · last posted 2026-08-13

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Study acronym: STAND
StatusActive, Not Recruiting
PhasePhase 3
Started2019-07-26
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.

Amendment record 96 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 96 times since 2019-01-21; most recent amendment 2026-07-08. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-04-02
Status change Recruiting→Active, Not Recruitingv60
2020-05-12
Status change Suspended→Recruitingv26
2020-04-26
Status change Recruiting→Suspendedv25
2019-06-29
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT03814746
Lead Sponsor Novartis Pharmaceuticals
Conditions Sickle Cell Disease (SCD)
Enrollment 254 participants
Start Date 2019-07-26
Primary Completion 2022-08-31 (estimated)
Study Completion 2026-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-13